204 related articles for article (PubMed ID: 11363880)
1. Ritonavir and saquinavir combination: 12-week data at ICAAC.
James JS
AIDS Treat News; 1996 Oct; (No 256):3. PubMed ID: 11363880
[TBL] [Abstract][Full Text] [Related]
2. Combination study of Invirase and Norvir starting.
AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361633
[No Abstract] [Full Text] [Related]
3. [Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs].
Jensen-Fangel S; Larsen L; Thomsen HF; Nielsen LP; Black FT; Obel N
Ugeskr Laeger; 1999 Mar; 161(12):1751-4. PubMed ID: 10210974
[TBL] [Abstract][Full Text] [Related]
4. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
Vazquez E
Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
[TBL] [Abstract][Full Text] [Related]
5. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R
Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
[TBL] [Abstract][Full Text] [Related]
6. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
[TBL] [Abstract][Full Text] [Related]
7. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
8. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
9. ["Double boosting" passes the test. LPV/r plus SQV in complicated salvage situation].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():85. PubMed ID: 15011607
[No Abstract] [Full Text] [Related]
10. [HIV: to administer protease inhibitors early].
Dtsch Med Wochenschr; 1996 Dec; 121(49):A49. PubMed ID: 8998916
[No Abstract] [Full Text] [Related]
11. [New formulation--fewer tablets--optimal effect].
Krankenpfl J; 2005; 43(7-10):249. PubMed ID: 16515318
[No Abstract] [Full Text] [Related]
12. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
13. A patient's guide to protease inhibitors.
Elperin A; Sax P
AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.
Jahnke N; Seminari E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 1999; 4(3):151-6. PubMed ID: 12731754
[TBL] [Abstract][Full Text] [Related]
15. [Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy].
MMW Fortschr Med; 2000; 142(3 Suppl):41. PubMed ID: 11012293
[No Abstract] [Full Text] [Related]
16. Combined protease results continue to hold up.
McGuire S
Posit Aware; 1997; 8(1):15. PubMed ID: 11364089
[TBL] [Abstract][Full Text] [Related]
17. Searching for the right dose of ritonavir-saquinavir.
TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860
[No Abstract] [Full Text] [Related]
18. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
[TBL] [Abstract][Full Text] [Related]
20. FDA notifications. Potential serious effect of combination saquinavir-ritonavir.
AIDS Alert; 2010 Apr; 25(4):45-6. PubMed ID: 20564774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
